Program
rilvegostomig
Also written as “Rilvegostomig”, “AZD2936” and “AZD9592 + Rilvegostomig”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Biliary Tract Neoplasms · Carcinoma, Hepatocellular · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 2222 open or running | phase 3since Oct 26, 2023 | Dec 13, 2018 | May 4, 2027phase 2 · NCT04379596 |
| Presage Biosciences | 21 open or running | early phase 1since Sep 1, 2020 | Sep 1, 2020 | Dec 2031early phase 1 · NCT04541108 |
- Named in AstraZeneca’s own pipeline as
rilvegostomig
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: Daiichi Sankyo and parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 8 studies since Dec 13, 2018.
- Oct 26, 2023Phase 3 study in Biliary Tract NeoplasmsAstraZeneca · NCT06109779 · 760 enrolled · United States, Australia, Belgium and more
- Apr 3, 2024Early phase 1 study in Squamous Cell Carcinoma of Head and NeckPresage Biosciences · NCT06366451 · 17 enrolled · United States
- Apr 5, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06357533 · 675 planned · United States, Australia, Austria and more
- May 21, 2024Phase 3 study in Biliary Tract NeoplasmsAstraZeneca · NCT06467357 · 620 planned · United States, Australia, Austria and more
- Aug 7, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06564844 · 25 enrolled · United States, Brazil, Canada and more
- Oct 3, 20242 phase 3 studiesAstraZeneca · NCT06627647, NCT06692738
- Dec 12, 2024Phase 3 study in HER2-positive Gastric CancerAstraZeneca · NCT06764875 · 840 planned · United States, Argentina, Australia and more
- Mar 7, 20253 phase 3 studiesAstraZeneca · NCT06868277, NCT06989112, NCT06921785
- May 5, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06996782 · 152 planned · United States, Belgium, Brazil and more
- Sep 3, 2025Phase 1 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyAstraZeneca · NCT07161414 · 40 planned · United States, South Korea, Spain and more
- Oct 1, 2025Phase 3 study in Biliary Tract NeoplasmsAstraZeneca · NCT07221253 · 1,100 planned · United States, Australia, Belgium and more
- Jan 16, 2026Phase 3 study in Stomach NeoplasmsAstraZeneca · NCT07431281 · 2,130 planned · United States, Australia, Austria and more
- Jun 10, 2026Phase 3 study in Carcinoma, Transitional CellAstraZeneca · NCT07720284 · 915 planned · United States, Australia, Brazil and more
- Nov 10, 2026Primary completion moved from 2026-08-28 to 2028-06-01Date moved laterphase 2 · +21 months · NCT04995523
Ahead
- May 4, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT04379596
- Jul 19, 2027Primary completion: phase 1 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyAstraZeneca · NCT07161414
- Sep 29, 2027Primary completion: phase 2 study in Breast NeoplasmsAstraZeneca · NCT05123482
- Nov 30, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT05702229
TargetBeta
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory …”NCIt, read by Claude
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory mot”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
Studies
All 24 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07720284Carcinoma, Transitional Cell · United States, Australia, Brazil and more | 3 | Recruiting | AstraZeneca | Sep 11, 2030 | 915 |
| NCT07431281Stomach Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | AstraZeneca | Aug 16, 2029 | 2,130 |
| NCT07221253Biliary Tract Neoplasms · United States, Australia, Belgium and more | 3 | Recruiting | AstraZeneca | Jul 31, 2029 | 1,100 |
| NCT07161414Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, South Korea, Spain and more | 1 | Recruiting | AstraZeneca | Jul 19, 2027 | 40 |
| NCT06996782Carcinoma, Non-Small-Cell Lung · United States, Belgium, Brazil and more | 2 | Recruiting | AstraZeneca | Feb 23, 2029 | 152 |
| NCT06921785Carcinoma, Hepatocellular · United States, Australia, Brazil and more | 3 | Recruiting | AstraZeneca | Mar 15, 2030 | 1,220 |
| NCT06989112Endometrial Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | AstraZeneca | Jan 19, 2029 | 600 |
| NCT06868277Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Jan 17, 2030 | 830 |
| NCT06764875HER2-positive Gastric Cancer · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Apr 27, 2029 | 840 |
| NCT06692738Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Jul 1, 2030 | 1,160 |
| NCT06627647Non-squamous Non-small Cell Lung Cancer · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Nov 18, 2030 | 1,160 |
| NCT06564844Carcinoma, Non-Small-Cell Lung · United States, Brazil, Canada and more | 3 | Active, not recruiting | AstraZeneca | Jul 10, 2026 | 25 |
| NCT06467357Biliary Tract Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | AstraZeneca | Jun 12, 2028 | 620 |
| NCT06357533Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Recruiting | AstraZeneca | Dec 28, 2029 | 675 |
| NCT06366451Squamous Cell Carcinoma of Head and Neck · United States | Early 1 | Completed | Presage Biosciences | Mar 25, 2026 | 17 |
| NCT06109779Biliary Tract Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Jan 2, 2029 | 760 |
| NCT05775159Carcinoma, Hepatocellular · United States, China, Hong Kong and more | 2 | Active, not recruiting | AstraZeneca | Oct 27, 2026 | 294 |
| NCT05702229Stomach Neoplasms · United States, China, Japan and more | 2 | Recruiting | AstraZeneca | Nov 30, 2027 | 163 |
| NCT05123482Breast Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | AstraZeneca | Sep 29, 2027 | 460 |
| NCT05061550Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Recruiting | AstraZeneca | May 28, 2030 | 630 |
| NCT04995523Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 2 | Active, not recruiting | AstraZeneca | Jun 1, 2028 | 212 |
| NCT04541108Squamous Cell Carcinoma of Head and Neck · United States | Early 1 | Active, not recruiting | Presage Biosciences | Dec 2031 | 15 |
| NCT04379596Stomach Neoplasms · United States, Brazil, Canada and more | 2 | Active, not recruiting | AstraZeneca | May 4, 2027 | 452 |
| NCT03819465Carcinoma, Non-Small-Cell Lung · United States, Austria, Belgium and more | 1 | Active, not recruiting | AstraZeneca | May 23, 2023 | 175 |
How it is read
Names in the registry
- “Rilvegostomig”, 20 entries
- “AZD2936”, 2 entries
- “AZD9592 + Rilvegostomig”, 2 entries
- “AZD8205 and AZD2936 (Rilvegostomig)”, 1 entry
- “AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 9 studies
- Stomach Neoplasms, 4 studies
- Biliary Tract Neoplasms, 3 studies
- Carcinoma, Hepatocellular, 2 studies
- Squamous Cell Carcinoma of Head and Neck, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.